Press Releases

Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

March 01, 2021

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease. Series A-2 led by Hatteras Venture Partners and Biohaven. Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors.

Read Full Release ❯

❮ Back to Press Releases